Director of Public Health Institute and Reader in Substance Use Epidemiology
areas of expertise
Jim McVeigh was appointed as the Director of Public Health Institute in November 2015. Jim has worked within health/public health for nearly 30 years, with an academic career starting in the University of Liverpool before moving to Liverpool John Moores University as a Research Assistant in 1999. Subsequently he has held various positions within Public Health Institute including Senior Lecturer, Reader, Deputy Director and most recently, Acting Director. He has gained significant management skills and leadership experience, while developing extensive links with external organisations and stakeholders at local, national and international level. Jim has an international reputation within his academic specialism of human enhancement drug use and has co-authored more than 100 research reports, 50 peer reviewed papers and been invited to deliver keynote presentations and plenary papers at some of the most influential national and international conferences
In addition to the reports and papers listed on this site Jim has also co-authored the following:
Sumnall H, McVeigh J & Evans-Brown M. Chapter 4 – Epidemiology of Use of Novel Psychoactive Substances, In: Dargan PI & Wood DM, Editor(s), Novel Psychoactive Substances, Academic Press, Boston, 2013, Pages 79-103
Evans-Brown M, McVeigh J, (2009) Anabolic steroid use in the general population of the United Kingdom.- In Elite Sport, Doping and Public Health. Edited by Møller V, Dimeo P, McNamee M. Odense: University of Southern Denmark Press :75-97
Jim McVeigh's Publications
Integrated Monitoring System Annual Report – Cheshire and Merseyside 2016/17
The annual report for the Integrated Monitoring System (IMS) details activity across Merseyside and Cheshire over the period of the 2016-17 financial year. The report provides information on presentations to needle and syringe programmes (NSPs) and other low threshold interventions delivered to individuals using drugs and/or alcohol, focussing on areas such as wellbeing, demographics and substances used. The data is presented in three distinct cohort groups; 1) individuals injecting psychoactive drugs, 2) individuals injecting steroids/IPEDs, 3) individuals accessing support related to alcohol or non-injecting drug use. Data from IMS is also cross-matched with the National Drug Treatment Monitoring System (NDTMS) and the Criminal Justice Dataset to provide a complete picture of activity within each of the nine Local Authority areas in Cheshire and Merseyside. The report also provides an overview of published and future research in the field at both a local and national level.
Image and Performance Enhancing Drugs 2016 National Survey Results
This report details the findings of the National IPEDinfo Survey 2016. The National IPEDinfo Survey is a study exploring image and performance drug use in Wales, England and Scotland. The survey is a Public Health Wales initiative working collaboratively with the Public Health Institute at Liverpool John Moores University, NHS Scotland, Nine Zero Five and Public Health England. All partners contributed to the development and delivery of the survey. Further information about the National IPED Info Survey can be found at http://ipedinfo.co.uk.
Integrated Monitoring System Annual Report – Cheshire and Merseyside 2015/16
This is the third annual report for the Integrated Monitoring System (IMS) which details activity across Merseyside and Cheshire over the period of the 2015-16 financial year. The report provides information on presentations to needle and syringe programmes (NSPs) and other low threshold interventions delivered to individuals using drugs and/or alcohol, focussing on areas such as wellbeing, demographics and substances used. The report also provides an overview of published and future research in the field at both a local and national level.
Jim McVeigh's Papers
A systematic review investigating the behaviour change strategies in interventions to prevent misuse of anabolic steroids
Journal of Health Psychology, 1–18, 2017.
Abstract We examined intervention effectiveness of strategies to prevent image- and performance-enhancing drug use. Comprehensive searches identified 14 interventions that met review inclusion criteria. Interventions were predominantly educational and delivered within school sport settings, but targeted a wide range of mediating factors. Identification of effective components was limited across studies by brief or imprecise descriptions of intervention content, lack of behavioural outcome measures and short-term follow-up times. However, studies with components in addition to information provision may be more promising. Interventions outside of sport settings are required to reflect the transition of this form of substance use to the general population.
Low levels of hepatitis C diagnosis and testing uptake among people who inject image and performance enhancing drugs in England and Wales, 2012-15
Drug and Alcohol Dependence Volume 179, 1 October 2017, Pages 83-86, 2017.
Abstract: Introduction: People injecting image and performance enhancing drugs (IPEDs) have traditionally not been perceived as being at high risk of hepatitis C virus (HCV) infection. However, recent studies indicate the HCV antibody (anti-HCV) prevalence in this group is 10-times that in the general population. HCV testing uptake and undiagnosed infections are examined using data from a voluntary unlinked-anonymous survey. Method: People injecting IPEDs across England and Wales completed a short bio-behavioural survey (2012–15). Anti-HCV status and self-reports of HCV testing were used in the analysis. Results: The participants median age was 31 years, 98% were men, 14% had also injected psychoactive drugs and the anti-HCV prevalence was 4.8% (N = 564). Among those who had never injected psychoactive drugs the anti-HCV prevalence was 1.4%; among those who had recently injected psychoactive drugs (preceding 12 months) prevalence was 39% and among those who had done this previously 14% (p < 0.001). Overall, 37% had been tested for HCV: among those who had recently injected psychoactive drugs 78% had been tested, as had 56% of those who had injected psychoactive drugs previously; 33% of those never injecting psychoactive drugs were tested (p < 0.001). Overall, 44% of those with anti-HCV were aware of this; however, only 14% of those who had never injected psychoactive drugs were aware. Conclusions: One-in-twenty people who inject IPEDs have anti-HCV. HCV infections among those who had never injected psychoactive drugs were mostly undiagnosed, though this group had a lower prevalence. Targeted HCV testing interventions are also needed for those injecting IPEDs.
Jim McVeigh, Emma Begley
Drugs: Education, Prevention and Policy, Pages 1-8, 2016.
Abstract: Aim: The aim of the paper was to identify changes in the extent and patterns of anabolic steroid use in the United Kingdom to better understand the public health implications within the context of the current health-related evidence base. Methods: Using the two time points between 1995 (prior to legislation changes in the United Kingdom) and 2015, a review of the evidence related to health harms was conducted, in conjunction with needle and syringe programme (NSP) data in Cheshire & Merseyside (UK) relating to anabolic steroid users. Findings: Dramatic increase in the number of anabolic steroid users accessing NSPs, 553 in 1995 to 2446 in 2015, now accounting for 54.9% of clients. With the inclusion of pharmacy NSPs, this rose to 5336 individual anabolic steroid users. Conclusions: Key changes in our knowledge during the 20 years, in particular, in relation to HIV prevalence, changes in the market and patterns of use make anabolic steroid use a public health concern. In the context of increasing numbers of injectors, there is a need for comprehensive interventions.